CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MGC Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MGC Pharmaceuticals Ltd
1202 Hay St
Phone: +61 863823390p:+61 863823390 PERTH, WAS  6005  Australia Ticker: MXCMXC

Business Summary
MGC Pharmaceuticals Ltd is an Australia-based pharmaceutical company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. It maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. It has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The Company's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Managing Director, Executive Director Roby R.Zomer 4/26/2022 2/15/2016
Deputy Chief Executive Officer, Chief Operating Officer YifatSteuer 10/4/2022 10/4/2022
Chief Commercial Officer RobertClements 7/19/2022 7/19/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Erin Resources Limited
Health Corporation Limited
Intramedics Pty Ltd
4 additional Business Names available in full report.

General Information
Outstanding Shares: 36,491,631 (As of 12/31/2023)
Shareholders: 10,119
Stock Exchange: ASX
Fax Number: +61 893892099


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024